Hdz-C123A

N/A

Report date: 2024/12/26 10:30:46

Base Information

Drug NameHdz-C123A
Drug Alias NameHdz-C123A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEukaryotic peptide chain release factor GTP-binding subunit ERF3A degradersAnti-CD123
TargetsEukaryotic peptide chain release factor GTP-binding subunit ERF3AInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Healzen Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Healzen Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A